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CHAPTER 4
METHOTREXATE FOR MAINTAINING 
REMISSION IN PEDIATRIC 
CROHN’S PATIENTS WITH PRIOR 
FAILURE OR INTOLERANCE TO 
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Background: Methotrexate (MTX) is an immunomodulating drug 
that can be used to maintain remission in patients with Crohn’s 
disease (CD), but data on efficacy and tolerability in children and 
teenagers are scarce. 
We evaluated the long-term efficacy and tolerability of MTX 
monotherapy after thiopurine therapy in pediatric CD patients. 
Methods: A multicentre cohort of pediatric MTX users who stopped 
thiopurines due to ineffectiveness or intolerance between 2002 
and 2012 were included and followed for at least 12 months. 
Relapse-free use was defined as steroid and biologic-free clinical 
remission after the introduction of MTX, and included  intentional 
discontinuation of successful therapy before the end of the 
observation period. 
Results: One hundred thirteen patients with CD in remission were 
followed while on MTX monotherapy, of which 75 (66%) had failed 
on thiopurines and 38 (34%) had stopped thiopurines due to side 
effects. Median age at the introduction of MTX was 14 years (range 
7 to 17), and 93% used the subcutaneous route. Kaplan–Meier 
analysis showed that 52% of the study cohort was still in steroid and 
biologic-free remission after 12 months of MTX monotherapy, with 
a difference that did not reach significance between thiopurine 
intolerant and thiopurine failing patients (P=0.21, log-rank test). 
 
Conclusions: The findings of this cohort study suggest that MTX 
is an effective immunomodulator to maintain remission after 
stopping thiopurines. MTX maintenance should be considered 
before stepping up to anti-TNF-alpha therapy. It is probably 
somewhat more effective in patients who stopped thiopurines due 





MATERIALS & METHODS 
Approximately 30% of patients with Crohn’s Disease (CD) present 
before the age of 19 years.(1) Treatment is aimed at inducing and 
maintaining remission of disease activity to ensure normal growth 
and pubertal development, and improving the quality of life of 
patients. European guidelines recommend the use of exclusive 
enteral nutrition or steroids to induce remission in children with 
luminal CD.(2) Thiopurines (azathioprine or mercaptopurine) 
or methotrexate are recommended to maintain steroid free 
remission.(2) Methotrexate (MTX) appears to be similarly effective 
in maintaining clinical remission as thiopurines,(3-9)  but side 
effects (including nausea, vomiting and elevated liver enzymes) 
have deterred its widespread use. Studies focusing on long-term 
benefits of MTX maintenance therapy in pediatric CD are lacking, 
and most published studies have lumped together children who 
stopped thiopurines due to intolerance (not true failures) and 
those who failed to respond to thiopurines(3,4,7-9) Unfamiliarity with 
MTX make pediatric gastroenterologists to frequently omit this 
drug and move on to infliximab, which has a limited duration 
of effect to maintain remission.(10,11) Increasingly tight healthcare 
budgets and concerns about the lymphoproliferative risk of long-
term use of thiopurines have ignited a renewed interest among 
adult and pediatric gastroenterologists  in MTX.  
We aimed to evaluate the long-term efficacy and tolerability of 
MTX monotherapy in a cohort of Dutch children and teenagers 
with CD and distinguished patients who failed on thiopurines and 
those who discontinued due to side effects. 
Study design & setting
In this retrospective multicentre cohort study we evaluated 
patient data from 6 university and 4 general teaching hospitals. 
The participating pediatric gastroenterologists are members 
of the Kids with Crohn’s and Colitis (KiCC) working group for 
Collaborative Research in the Netherlands. Together they treat 
about two-thirds of the total pediatric CD population in the 
Netherlands. Data were entered on site in an electronic case 
report form that was specifically designed for this research project 
and included patient and disease characteristics (expressed 
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according to the Paris classification(12)), previous therapies and 
disease course. We especially focused on the period of exposure 
to MTX, clinical efficacy (expressed as relapse-free use) and 
tolerability.  
Participants 
We identified children and teenagers (up to the age of 17) with 
CD who were treated with MTX after thiopurine ineffectiveness 
or intolerance between 2002 and 2012. For patients with several 
episodes of MTX exposure, we only analyzed the first episode. 
Those who used MTX primarily to treat a non-IBD indication (e.g. 
rheumatoid arthritis) and those on anti-TNF-alpha co-treatment 
were excluded from analysis.
Definitions & outcome measures
Primary outcome measure was relapse-free MTX use, which was 
defined as either steroid or biologics-free clinical remission after 
the introduction of MTX, and included intentional discontinuation 
of successful MTX therapy before the end of the observation period. 
Among patients who discontinued successful MTX therapy we 
distinguished those who did so per provider recommendation 
and those who self-initiated discontinuation. Whenever available, 
endoscopic and pathohistologic reports were used to confirm 
relapse. As this is an uncommon strategy to determine relapse in 
pediatric CD, we based this diagnosis mainly on a Pediatric Crohn’s 
Disease Activity Index (PCDAI) score > 10 points in combination 
with the initiation of steroids, anti-TNF-alpha therapy or exclusive 
enteral nutrition.  
Secondary outcome measures included the occurrence of side 
effects, reasons for discontinuation, and identification of risk factors 
for relapse under MTX monotherapy. Early failure of MTX-treatment 
was defined as relapse within 6 months after initiation of MTX.
Statistical analysis 
Data were analyzed with SPSS for Windows, version 20 (SPSS Inc, 
Chicago, IL). All tests were two-sided and the level of significance 
used was P < 0.05. Time-to-event data were analyzed by Kaplan-
Meier and log-rank test. Stepwise logistic regression with backward 
elimination was planned to determine predictors of early MTX 
failure. Candidate predictors with P < 0.10 in bivariate analysis were 
selected for use in the multivariate analysis. This level was chosen 




Median age at diagnosis (range in years)
IBD-related comorbidity
 ■ Joint inflammation
 ■ Eye manifestations 
 ■ Skin manifestations
Initial remission induction therapy







Thiopurine switch to mercaptopurine prior to MTX
Median number of relapses prior to MTX (range)




 ■ B1, p
 ■ B2, p
 ■ B2B3,p
Growth delay (according to Paris Classification(12))
Characteristics
B1: Nonstricturing, nonpenetrating disease, B2: Stricturing 
disease, B3: penetrating disease, p: perianal disease modifier, 
B2B3: both penetrating and stricturing disease either at the 
same or different times.







































































This study was not subject to “Medical Research Involving Human 
Subjects Act”, as it involved the study collection of data generated 
by routine medical care. The data were collected and recorded 
by the investigators in such a manner that subjects could not be 
identified, directly or through identifiers linked to the subjects.
RESULTS
Patient characteristics 
We identified 148 children and teenagers who started MTX 
therapy between 2002 and 2012. A total of 35 children were 
excluded from analysis for anti-TNF-alpha cotreatment (n=29), 
MTX use primarily for a non-IBD indication (n=3), or missing 
values (n=3). A total of 113 methotrexate users were ultimately 
included, of which 75 (66%) had failed on thiopurines and 
38 (34%) discontinued thiopurines due to side effects. Two-
thirds were initially treated with exclusive enteral nutrition to 
induce remission, and 88% received azathioprine as their first 
immunomodulator. The majority of cases had nonstricturing, 
nonpenetrating luminal CD (table 1). 
MTX was initiated at a median age of 14 years (range 7 to 17) 
and after a median disease duration of 2 years (range 1 month 
to 11 years) (table 2). Seventy-one percent of the patients who 
discontinued thiopurine monotherapy because of intolerance 
had drug-induced acute pancreatitis. Most patients received 
MTX subcutaneously (93%) at initiation, with a median dosage 
of 15 mg/wk (range 5 to 25), which is equivalent to 11 to 15 mg/m2 
(body surface area). All patients in this study cohort received folate 
within 24 to 48 hours after the administration of MTX.
Duration of methotrexate use
Eighteen months after introduction over 50% of our cohort was 
still using MTX. At 3, 6, 12 and 24 months, the proportions of 
patients on continuous use of MTX were 94% (95% CI: 89 to 98), 
83% (95% CI: 76 to 90), 65% (95% CI: 56 to 73) and 44% (95% CI: 35 
to 54) respectively. A fifth of our cohort used MTX for more than 3 
years.
Among those who discontinued MTX, 45% did so because of 
ineffectiveness, while 47% had intolerance. The remainder stopped 
successful MTX therapy per provider recommendation (n=5) or on 
their own initiative (n=2). 
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Reason for initiation of MTX
 ■ Thiopurine ineffectiveness 
 ■ Thiopurine intolerance 
  □ Pancreatitis 
  □ Hepato/myeolotoxicity
  □ Other complaints
MTX route of administration 
 ■ Subcutaneous 
 ■ Oral
Median age at initiation of MTX (range in years)











Table 2. Patient characteristics at initiation of methotrexate maintenance therapy (n=113)
Efficacy of methotrexate
Steroid and biologics-free MTX use is shown in figure 1. Nine 
patients were excluded from this time-to-event analysis as they 
did not reach remission while using MTX. Fifty-two percent of 
the total study cohort (95% CI: 42 to 62%) was still in steroid and 
biologic-free remission after 12 months of MTX monotherapy 
(line not shown), with a difference that did not reach significance 
between thiopurine intolerant and thiopurine failing patients 
(P=0.21, log-rank test).  In the first group the percent of relapse-
free children at 6, 12 and 24 months was respectively  85% (95% 
CI 72 to 97%), 62% (95% CI 44 to 79%) and 38% (95% CI 20 to 56%), 
while in the group who previously failed on thiopurines the 
percent of relapse-free children was respectively 67% (95% CI 66 
to 69%), 48% (95% CI 36 to 60%) and 25% (95% CI 14 to 37%) . We 
intended to construct a prognostic model for discontinuation 
of MTX-treatment. Stepwise logistic regression with backward 
elimination was planned, but in the bivariate model only one 
significant risk factor was identified. Multivariate analysis was 
therefore not executed. Ineffectiveness of thiopurine before 
intiation of MTX was a significant risk factor for subsequent early 
MTX failure (odds ratio 2.6 (95% CI 1.1 to 6.5), P= 0,036). 
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Safety and prevention 
Sixty-eight of 113 patients reported side effects. The commonest 
complaint was nausea and/or vomiting around MTX 
administration (figure 2). This resulted in discontinuation of MTX 
therapy in 21 patients. Thirty patients received ondansetron. In 
the majority of cases (n=18) this premedication strategy was only 
started after the appearance of side effects. Six of 113 patients had 
transient elevation of transaminases, of which one developed 
regenerative nodular liver hyperplasia. In two cases transaminitis 
resolved after dose tapering or temporary discontinuation. In the 
remaining four MTX was permanently discontinued.
Figure 1. Kaplan-Meier plot demonstrating the percent of methotrexate users who 
maintained remission. Children with Crohn's disease who failed on thiopurines 
(solid line) are compared with those who discontinued thiopurines due to 
side effects (dotted line). Event is defined as date of first relapse, necessitating 
steroids, exclusive enteral nutrition or anti-TNF-alpha therapy; censor is defined as 
discontinuation of methotrexate due to side effects or end of observation period. 
The numbers on the lowest two lines indicate the number of patients being 




We studied the efficacy and tolerability of methotrexate 
monotherapy in children with CD who discontinued thiopurines. 
Twelve months after initiation of MTX 52% of the patients was still 
free from relapse. MTX efficacy in the group of patients who had 
thiopurine intolerance was not superior to MTX efficacy in the 
group of patients with thiopurine failure. Nausea and/or vomiting 
around MTX administration were the most common side effects 
prompting 19% of patients to stop MTX. 
Comparison with other studies  
To our knowledge this is the largest study that evaluated the 
efficacy of MTX after discontinuation of thiopurines and divided 
MTX users into those who failed on thiopurines and those who 
stopped due to side effects. Most papers that have been published 
to date (table 3) were case series describing the proportion 
of patients in remission at preset time points, and may have 
underestimated its real protective effect. In previously published 
studies the percentage of patients still in remission after 12 
months ranged from 33 to 48%.(3-9,13,14)  In order to evaluate the 













Mack, 1998 (3) 








Age at start 
MTX (yrs)
15.1 ± 3.1 (mean, SD)
Age at diagnosis, 
11.1 ± 2.3 (mean, SD); 
duration until start 
MTX, 3.1 ± 2.2
13.8 ± 2.7 (mean, SD)
15.8 (median, range 
12 to 16.9)
14.5 ± 3.1 (mean, SD)
13.8 ± 0.7 (mean, SD)
Unknown



















Table 3. Overview of studies reporting methotrexate efficacy after thiopurine use in 



















PCDAI –score and steroid 
requirement
HBI and steroid 
requirement
PCDAI-score, steroid 
requirement and height 
velocity
Clinical symptoms and 
inflammatory markers
HBI and steroid 
requirement
Steroid/Infliximab free 
remission determined by 
PGA
Remission determined 
by PGA, without surgery, 
TP, biologicals or 
corticosteroids
Remission determined by 
PCDAI  or inactive perianal 
fistula, without treatment 
escalation or surgery 
surgery
64% showed improvement 
(PCDAI-score decreased 
from baseline)
39%, 49% and 45% 
complete remission 
at 3, 6 and 12 months 
respectively
62% and 53% in full 
remission (PCDAI < 
10) at 6 and 12 months 
respectively. 42% in 
remission at both 6 and 12 
months
7 children showed 
clinical and biochemical 
improvement
64% achieved remission, 
24% partial response 
and 48% in remission or 
response at 12 months
48% and 33% in remission 
at 6 and 12 months 
respectively
35% had sustained clinical 
remission for 12-48 
months
34% had sustained 




true relapse-preventing effect of MTX, patients should ideally only 
be included in a study cohort after they have reached remission, 
have stopped steroids or exclusive enteral feeding, and use MTX 
monotherapy (figure 3).(15) Whether this is done in previously 
published studies is not clearly described. We used a strict 
case definition for clinical remission that was based on PCDAI-
score < 10 (and where applicable fecal calprotectin levels in the 
normal range, i.e. < 250 μg/g) without treatment escalation (i.e. 
adding steroids, exclusive enteral nutrition or anti-TNF-alpha).(16,17) 
Secondly, in contrast to previously published studies we classified 
patients who discontinued successful MTX use per provider 
recommendation or on their own initiative under relapse-free MTX 
use and not under treatment failure.
Methodological limitations
Relapse-free MTX use was our primary outcome, but due to 
the retrospective nature of this study discontinuation of the 
drug was not determined by protocol. Physicians with a pre-
existing bias against MTX may have seen the appearance of side 
effects as a confirmation of the patient-unfriendly medicine 
and were perhaps easier in moving forward to anti-TNF therapy. 
Others may have put more effort in treating the side effects, 
e.g. with ondansetron.(18) Another possible restriction of this 
study related to the method of retrospective chart review, which 
may have affected the reliability of reporting of side effects 
and non-adherence. In addition the impact of MTX treatment 
on endoscopic disease activity (i.e. mucosal healing) was not 
assessed.
Implications for pediatric practice 
Few pediatric gastroenterologists prescribe MTX in CD patients 
on a regular basis, in contrast to rheumatologists in the treatment 
of patients with rheumatoid arthritis.(19) Skepticism about 
its effectiveness, concerns about adverse events and lack of 
experience with the drug are the main reasons to omit MTX as a 
second line immunomodulator and to prescribe more expensive 
anti-TNF-alpha antibodies following thiopurine ineffectiveness 
or intolerance. In the Netherlands annual drug costs to treat a 
40 kg weighing child with CD is €1381 for weekly subcutaneous 
injections of methotrexate and €7656 for 8-weekly intravenous 
infliximab infusions.(20) In this calculation we did not take into 
account the additional costs for intravenous infusions during 
hospital day admissions. The findings of this cohort study suggest 
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Figure 3. Position of methotrexate in step-up treatment scheme 
for pediatric luminal CD used in this study cohort15 EEN, Exclusive 
enteral nutrition; MTX, methotrexate. Relapse preventing effect of 
MTX is assessable once MTX montherapy is initiated 
that it is worthwhile to consider MTX to maintain remission, before 
stepping up to anti-TNF-alpha antibodies. Over 50% of the study 
cohort was relapse free a year after introducing MTX and a fifth of 
the cohort used it satisfactorily for more than 3 years. 
A recently published multi-center observational study from North-
America showed that MTX is being prescribed with increasing 
frequency as first choice immunomodulator. Many pediatric 
gastroenterologists seem to become uncomfortable with 
thiopurines usage, particularly in conjunction with anti-TNF-alpha 
antibodies.(13)
Nausea and/or vomiting were the most common side effects 
following MTX and an important reason to stop MTX, even if 
the treatment was successful in maintaining remission. Many 
children will develop anticipatory vomiting, which is vomiting 
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prior to the administration of MTX. It is a learned response that is 
more likely to happen in children who have a history of motion 
sickness. Administration of ondansetron from the outset one 
hour prior to injection may reduce anticipatory nausea and could 
improve tolerance.(18) In our cohort ondansetron was only used 
in 30 patients and mostly after the appearance of complaints. 
We did not observe a statistically significant difference between 
preemptive and post hoc administration of ondansetron 
regarding MTX tolerance. 
Abnormal liver biochemistry was seen in 5% of our cohort. Dose 
reduction or a short MTX holiday could solve the transaminitis, 
but in the majority of cases the patient was advised to 
discontinue MTX permanently. In a recently published systematic 
review that included 457 pediatric CD cases treated with MTX, 
approximately 10% (95% CI 5 to 19%) had signs of transaminitis.
(21 Patients in stable remission should have their alanine aminot)
ransferase monitored periodically. Several authors recommend 
folate supplementation in order to decrease the severity of 
gastrointestinal symptoms and liver toxicity.(22-24) 
Whether MTX can be administered orally for maintaining 
remission has been largely debated in the literature. Bioavailability 
of oral MTX varies highly, in particular in CD patients with small-
bowel disease. A recently published retrospective cohort study 
among children with CD treated with oral or subcutaneous MTX 
suggests that MTX should be commenced subcutaneously and 
could be switched to the oral route once complete remission is 
reached.(14) The majority of CD patients in our cohort (93%) were 
treated with subcutaneous MTX.(15) The mean weekly dose was 15 
mg/m2 body surface area and was similar to the dosage used in 




This cohort study among pediatric CD patients who received 
MTX monotherapy following discontinuation of thiopurines 
showed that 52% was still relapse-free 12 months after initiation, 
decreasing to 29% after 24 months. Nausea and vomiting around 
administration was observed in half of the cohort, and was 
an important reason to discontinue MTX, despite steroids and 
biologics free clinical remission. Our findings suggest that it is 
worthwhile to consider MTX to maintain remission, especially in 
those who are thiopurine intolerant, before stepping up to anti-
TNF-alpha antibodies. Preemptive treatment with an anti-emetic 
may improve MTX tolerance.
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